Response rates for rTNSS ranged from 91% to 100% in the RPN3 group and 84% to 96% in the RAPN group.<h4>Conclusion</h4>Both RAPN and RPN3 are effective in treating chronic rhinitis unresponsive to medication. The gene discussed is PSMD3; the disease is chronic rhinitis.